Plasma Parathyroid Hormone and Risk of Congestive Heart Failure in the Community

  • Emil Hagström
    Uppsala Clinical Research Center, Uppsala University , 751 85, Uppsala ,
  • Erik Ingelsson
    Department of Public Health and Caring Sciences/Geriatrics, Uppsala University , Uppsala ,
  • Johan Sundström
    Uppsala Clinical Research Center, Uppsala University , 751 85, Uppsala ,
  • Per Hellman
    Department of Surgical Sciences, Uppsala University , Uppsala ,
  • Tobias E. Larsson
    Department of Clinical Science, Intervention and Technology, Karolinska Institutet , Stockholm ,
  • Lars Berglund
    Uppsala Clinical Research Center, Uppsala University , 751 85, Uppsala ,
  • Håkan Melhus
    Department of Medical Sciences, Uppsala University , Uppsala ,
  • Claes Held
    Uppsala Clinical Research Center, Uppsala University , 751 85, Uppsala ,
  • Karl Michaëlsson
    Uppsala Clinical Research Center, Uppsala University , 751 85, Uppsala ,
  • Lars Lind
    Department of Medical Sciences, Uppsala University , Uppsala ,
  • Johan Ärnlöv
    Department of Public Health and Caring Sciences/Geriatrics, Uppsala University , Uppsala ,

書誌事項

公開日
2010-11-01
権利情報
  • https://academic.oup.com/pages/standard-publication-reuse-rights
DOI
  • 10.1093/eurjhf/hfq134
公開者
Oxford University Press (OUP)

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Aims</jats:title> <jats:p>In experimental studies parathyroid hormone (PTH) has been associated with underlying causes of heart failure (HF) such as atherosclerosis, left ventricular hypertrophy, and myocardial fibrosis. Individuals with increased levels of PTH, such as primary or secondary hyperparathyroidism patients, have increased risk of ischaemic heart disease and HF. Moreover, increasing PTH is associated with worse prognosis in patients with overt HF. However, the association between PTH and the development HF in the community has not been reported.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods and Results</jats:title> <jats:p>In a prospective, community-based study of 864 elderly men without HF or valvular disease at baseline (mean age 71 years, the ULSAM study) the association between plasma (P)-PTH and HF hospitalization was investigated adjusted for established HF risk factors (myocardial infarction, hypertension, diabetes, electrocardiographic left ventricular hypertrophy, smoking, and hypercholesterolaemia) and variables reflecting mineral metabolism (S-calcium, S-phosphate, P-vitamin D, S-albumin, dietary calcium and vitamin D intake, physical activity, glomerular filtration rate, and blood draw season). During follow-up (median 8 years), 75 individuals were hospitalized due to HF. In multivariable Cox-regression analyses, higher P-PTH was associated with increased HF hospitalization (hazard ratio for 1-SD increase of PTH, 1.41, 95% CI 1.12–1.77, P = 0.003). Parathyroid hormone also predicted hospitalization in participants without apparent ischaemic HF and in participants with normal P-PTH.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>In a large community-based sample of elderly men, PTH predicted HF hospitalizations, also after accounting for established risk factors and mineral metabolism variables.</jats:p> <jats:p>Our data suggest a role for PTH in the development of HF even in the absence of overt hyperparathyroidism.</jats:p> </jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ